Prana has today announced that is has received a A$3.3 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.

Notice of General Meeting 2019

Prana receives first orphan drug designation from the FDA for the treatment of Multiple System Atrophy

Prana Biotechnology BSC Presntation 20180107 FINAL

Prana's Chief Medical Officer Dr David Stamler, MD will present at the Biotech Showcase in San Francisco on Monday 7th January, US Pacific Standard Time.

Prana Biotechnology has today announced that it has entered into a securities purchase agreement for a lead investment by Boston based Life Biosciences LLC (“Life Biosciences”) to raise up to approximately A$44.5 million

2018_11_16 AGM Presentation 2018

Prana invites investors unable to attend the Company’s Annual General Meeting to participate via teleconference.

PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model of Multiple System Atrophy

https://www.sec.gov/cgi-bin/viewer?action=view&cik=1131343&accession_number=0001144204-18-047425&xbrl_type=v